CHRISTOPHER BROOKE - 15 Nov 2022 Form 3 Insider Report for AYTU BIOPHARMA, INC (AYTU)

Role
Chief Operating Officer
Signature
/s/ Mark Oki as attorney-in-fact for Christopher Brooke
Issuer symbol
AYTU
Transactions as of
15 Nov 2022
Net transactions value
$0
Form type
3
Filing time
15 Nov 2022, 08:24:46 UTC
Next filing
15 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AYTU Common Stock 1,167,147 15 Nov 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AYTU Employee Stock Option (Right to Buy) 15 Nov 2022 Common Stock 135,000 $0.2000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 27,413 unvested restricted shares granted on April 12, 2021. The initial grant was for 73,100 restricted shares, with one-quarter vesting on the grant date. The remaining restricted shares vest quarterly thereafter, at 1/12th of the original grant, with full vesting on April 12, 2024.
F2 Full vesting is subject to continued service through each applicable vesting date.
F3 The options were granted on October 1, 2022, and vest as follows: One-third of the options vest on October 1, 2023. The remaining options vest in equal monthly installments, until fully vested on October 1, 2025.

Remarks:

Exhibit 24.1 Power of Attorney